← Back to Screener
Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)
Price$86.40
Value ScoreD
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-28.72%
Price vs S&P 500 (4W)-8.24%
VGM Score51.67
Market Capitalization$5.93B
All Metrics
Book Value / Share (Quarterly)$3.47
P/TBV (Annual)26.99x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)100.22%
Cash Flow / Share (Quarterly)$-1.76
Price vs S&P 500 (YTD)-27.44%
Gross Margin (TTM)89.41%
Net Profit Margin (TTM)-93.33%
EPS (TTM)$-3.06
10-Day Avg Trading Volume0.49M
EPS Excl Extra (TTM)$-3.06
EPS (Annual)$-3.02
ROI (Annual)-51.97%
Gross Margin (Annual)89.73%
Net Profit Margin (5Y Avg)-703.67%
Cash / Share (Quarterly)$4.98
Revenue Growth QoQ (YoY)83.81%
ROA (Last FY)-40.93%
Revenue Growth TTM (YoY)58.67%
EBITD / Share (TTM)$-2.96
ROE (5Y Avg)-86.59%
Operating Margin (TTM)-90.89%
Cash Flow / Share (Annual)$-1.74
P/B Ratio24.94x
P/B Ratio (Quarterly)24.99x
Net Income / Employee (Annual)$-474,700
EV / Revenue (TTM)27.50x
Net Interest Coverage (TTM)-36.06x
ROA (TTM)-44.99%
EPS Incl Extra (Annual)$-3.02
Current Ratio (Annual)4.41x
Quick Ratio (Quarterly)3.63x
3-Month Avg Trading Volume0.79M
52-Week Price Return30.55%
Revenue / Employee (TTM)$524,600
Tangible BV / Share (Quarterly)$3.40
P/S Ratio (Annual)31.23x
Asset Turnover (Annual)0.40x
52-Week High$122.20
Operating Margin (5Y Avg)-1339.99%
EPS Excl Extra (Annual)$-3.02
CapEx CAGR (5Y)35.32%
Tangible BV CAGR (5Y)12.11%
26-Week Price Return-20.80%
Quick Ratio (Annual)4.01x
13-Week Price Return-5.53%
Total Debt / Equity (Annual)0.40x
Current Ratio (Quarterly)4.17x
Enterprise Value$5.97B
Asset Turnover (TTM)0.48x
Book Value / Share Growth (5Y)1.29%
Revenue / Employee (Annual)$458,400
Inventory Turnover (Annual)0.88x
Pretax Margin (Annual)-103.31%
Cash / Share (Annual)$5.79
3-Month Return Std Dev52.37%
Gross Margin (5Y Avg)87.94%
Net Income / Employee (TTM)$-489,600
ROE (Last FY)-72.79%
Net Interest Coverage (Annual)-43.35x
EPS Basic Excl Extra (Annual)$-3.02
Receivables Turnover (TTM)8.35x
Total Debt / Equity (Quarterly)0.46x
EPS Incl Extra (TTM)$-3.06
Receivables Turnover (Annual)8.51x
ROI (TTM)-59.08%
P/S Ratio (TTM)27.29x
Pretax Margin (5Y Avg)-703.42%
Revenue / Share (Annual)$2.92
Tangible BV / Share (Annual)$3.94
Price vs S&P 500 (52W)6.19%
Year-to-Date Return-19.28%
5-Day Price Return-1.67%
EPS Normalized (Annual)$-3.02
ROA (5Y Avg)-46.27%
Net Profit Margin (Annual)-103.57%
Month-to-Date Return-2.17%
Cash Flow / Share (TTM)$-3.23
EBITD / Share (Annual)$-2.93
Operating Margin (Annual)-101.19%
LT Debt / Equity (Annual)0.37x
ROI (5Y Avg)-58.33%
LT Debt / Equity (Quarterly)0.41x
EPS Basic Excl Extra (TTM)$-3.06
P/TBV (Quarterly)25.54x
P/B Ratio (Annual)26.45x
Inventory Turnover (TTM)0.96x
Pretax Margin (TTM)-92.89%
Book Value / Share (Annual)$4.02
Price vs S&P 500 (13W)-13.79%
Beta1.96x
Revenue / Share (TTM)$3.19
ROE (TTM)-86.53%
52-Week Low$60.70
vGradeD
gGradeA
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.83est. -0.87
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RYTMRhythm Pharmaceuticals, Inc. Common Stock | D | A | C | $86.40 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing precision medicines for rare neuroendocrine and metabolic disorders. The company commercializes IMCIVREE (setmelanotide), an approved MC4R agonist for treating hyperphagia and severe obesity caused by rare genetic deficiencies in the MC4R pathway. Its pipeline includes two next-generation MC4R agonists designed to avoid hyperpigmentation and candidate therapies for congenital hyperinsulinism.